172 related articles for article (PubMed ID: 26536105)
41. Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice.
Khan MA; Khan A; Owais M
FEMS Immunol Med Microbiol; 2006 Feb; 46(1):63-9. PubMed ID: 16420598
[TBL] [Abstract][Full Text] [Related]
42. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model.
Zuluaga AF; Agudelo M; Cardeño JJ; Rodriguez CA; Vesga O
PLoS One; 2010 May; 5(5):e10744. PubMed ID: 20505762
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans.
Petraitis V; Petraitiene R; Kelaher AM; Sarafandi AA; Sein T; Mickiene D; Bacher J; Groll AH; Walsh TJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3959-67. PubMed ID: 15388459
[TBL] [Abstract][Full Text] [Related]
44. Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.
Cojutti PG; Lugano M; Righi E; Della Rocca G; Bassetti M; Hope W; Pea F
Eur J Clin Pharmacol; 2018 Nov; 74(11):1449-1459. PubMed ID: 30032414
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis.
Aviles P; Falcoz C; San Roman R; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 Sep; 44(9):2333-40. PubMed ID: 10952576
[TBL] [Abstract][Full Text] [Related]
46. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
47. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis.
Warn PA; Sharp A; Morrissey G; Denning DW
J Antimicrob Chemother; 2005 Sep; 56(3):590-3. PubMed ID: 16046462
[TBL] [Abstract][Full Text] [Related]
48. Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: the case of meropenem.
Agudelo M; Rodriguez CA; Pelaez CA; Vesga O
Antimicrob Agents Chemother; 2014; 58(2):1005-18. PubMed ID: 24277034
[TBL] [Abstract][Full Text] [Related]
49. The comparative bioavailability of a generic and the innovator fluconazole preparations in healthy Thai volunteers.
Teekachunhatean S; Rojanastein N; Manorot M; Sangdee C; Apisariyakul A; Ajayutphokin U
J Med Assoc Thai; 1998 Oct; 81(10):772-8. PubMed ID: 9803068
[TBL] [Abstract][Full Text] [Related]
50. Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach.
Gharibian KN; Mueller BA
Clin Nephrol; 2016 Jul; 86(7):43-50. PubMed ID: 27251341
[TBL] [Abstract][Full Text] [Related]
51. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.
Wring SA; Randolph R; Park S; Abruzzo G; Chen Q; Flattery A; Garrett G; Peel M; Outcalt R; Powell K; Trucksis M; Angulo D; Borroto-Esoda K
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137806
[TBL] [Abstract][Full Text] [Related]
52. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.
Louie A; Kaw P; Banerjee P; Liu W; Chen G; Miller MH
Antimicrob Agents Chemother; 2001 Feb; 45(2):485-94. PubMed ID: 11158745
[TBL] [Abstract][Full Text] [Related]
53. Clinical and mycological responses to fluconazole and fluconazole MIC in oropharyngeal candidiasis in HIV-infected patients.
Bussaratid V; Tansupasawasdikul S; Simpson A; Pitisuttithum P; Phonrat B; Howe P; White NJ
J Med Assoc Thai; 2002 Jul; 85(7):757-64. PubMed ID: 12296406
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice.
Ninomiya M; Mikamo H; Tanaka K; Watanabe K; Tamaya T
J Antimicrob Chemother; 2005 Apr; 55(4):587-90. PubMed ID: 15728144
[TBL] [Abstract][Full Text] [Related]
55. Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model.
Zuluaga AF; Rodriguez CA; Agudelo M; Vesga O
BMC Res Notes; 2015 Oct; 8():546. PubMed ID: 26445936
[TBL] [Abstract][Full Text] [Related]
56. Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infection.
Han S; Kim J; Yim H; Hur J; Song W; Lee J; Jeon S; Hong T; Woo H; Yim DS
Antimicrob Agents Chemother; 2013 Feb; 57(2):1006-11. PubMed ID: 23254425
[TBL] [Abstract][Full Text] [Related]
57. [Plasma and tissue concentrations of fluconazole: discussion of the breakpoint problem].
Pittrow L; Penk A
Mycoses; 1996; 39 Suppl 2():58-65. PubMed ID: 9198747
[TBL] [Abstract][Full Text] [Related]
58. Effect of prolonged fluconazole treatment on Candida albicans in diffusion chambers implanted into mice.
Sohnle PG; Hahn BL
Antimicrob Agents Chemother; 2002 Oct; 46(10):3175-9. PubMed ID: 12234841
[TBL] [Abstract][Full Text] [Related]
59. Fluconazole: optimized antifungal therapy based on pharmacokinetics.
Silling G
Mycoses; 2002; 45 Suppl 3():39-41. PubMed ID: 12690970
[TBL] [Abstract][Full Text] [Related]
60. Effects of fluconazole on viable cell count in experimental intraperitoneal Candida abscesses.
Mikamo H; Hua YX; Hayasaki Y; Sato Y; Tamaya T
J Infect Chemother; 2000 Sep; 6(3):144-7. PubMed ID: 11810554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
